Rafael Ruiz-Salmerón-rekin lankidetzan egindako argitalpenak (6)

2020

  1. Corrigendum: Cost-Effective, Safe, and Personalized Cell Therapy for Critical Limb Ischemia in Type 2 Diabetes Mellitus (Frontiers in Immunology, (2019), 10, 10.3389/fimmu.2019.01151)

    Frontiers in Immunology

2019

  1. Cost-effective, safe, and personalized cell therapy for critical limb ischemia in type 2 diabetes mellitus

    Frontiers in Immunology, Vol. 10, Núm. JUN

2018

  1. PDGF Restores the Defective Phenotype of Adipose-Derived Mesenchymal Stromal Cells from Diabetic Patients

    Molecular Therapy, Vol. 26, Núm. 11, pp. 2696-2709

2013

  1. Adipose mesenchymal stromal cells isolated from type 2 diabetic patients display reduced fibrinolytic activity

    Diabetes, Vol. 62, Núm. 12, pp. 4266-4269

2011

  1. Angiographic demonstration of neoangiogenesis after intra-arterial infusion of autologous bone marrow mononuclear cells in diabetic patients with critical limb Ischemia

    Cell Transplantation, Vol. 20, Núm. 10, pp. 1629-1639

2008

  1. Cell therapy for diabetes mellitus: An opportunity for stem cells?

    Cells Tissues Organs